The Europe antiviral drugs market size exceeded USD 8.5 million in 2020 and is projected to register a growth of over -1.9% from 2021 to 2027 as incidence of COVID-19 has significantly increased the usage of anti-viral drugs.

Europe Antiviral Drugs Market Size | Growth Forecasts 2027

Europe Antiviral Drugs Market Size By Age Group (Pediatric, Adult, Geriatric), By Drug Class (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors), By Indication (Influenza, HIV AIDS, Hepatitis, Herpes Simplex Virus [HSV], Coronavirus Infection), By Type (Branded, Generic), Research Report, Country Outlook (Germany, UK, France, Italy, Spain, Russia, Poland, Netherlands, Sweden, Switzerland), Price Trends, Growth Prospects, Competitive Industry Share & Forecasts, 2021 – 2027 

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology

1.1&nbsp;&nbsp;&nbsp; Market definitions

1.2&nbsp;&nbsp;&nbsp; Forecast assumptions

1.3&nbsp;&nbsp;&nbsp; Data sources

1.3.1&nbsp;&nbsp;&nbsp; Secondary

1.3.1.1&nbsp;&nbsp;&nbsp; Paid sources

1.3.1.2&nbsp;&nbsp;&nbsp; Unpaid sources

1.3.2&nbsp;&nbsp;&nbsp; Primary

Chapter 2&nbsp;&nbsp;&nbsp;Market Summary

2.1&nbsp;&nbsp;&nbsp; Europe anti-viral drugs industry summary, 2016 &ndash; 2027

2.1.1&nbsp;&nbsp;&nbsp; Country trends

2.1.2&nbsp;&nbsp;&nbsp; Drug class trends

2.1.3&nbsp;&nbsp;&nbsp; Indication trends

2.1.4&nbsp;&nbsp;&nbsp; Type trends

2.1.5&nbsp;&nbsp;&nbsp; Age group trends

Chapter 3&nbsp;&nbsp;&nbsp;Market Analysis

3.1&nbsp;&nbsp;&nbsp; Industry segmentation

3.2&nbsp;&nbsp;&nbsp; Industry outlook, 2016 - 2027

3.3&nbsp;&nbsp;&nbsp; Major factor analysis

3.3.1&nbsp;&nbsp;&nbsp; Growth drivers

3.3.1.1&nbsp;&nbsp;&nbsp; Increasing prevalence of viral infection

3.3.1.2&nbsp;&nbsp;&nbsp; Presence of large geriatric population

3.3.1.3&nbsp;&nbsp;&nbsp; Increasing research and development activities in the field of Anti-viral drugs

3.3.2&nbsp;&nbsp;&nbsp; Industry pitfalls and challenges

3.3.2.1&nbsp;&nbsp;&nbsp; Rising awareness about preventive drug treatment

3.3.2.2&nbsp;&nbsp;&nbsp; Presence of generics

3.4&nbsp;&nbsp;&nbsp; Analysis of COVID-19 impact on the industry

3.5&nbsp;&nbsp;&nbsp; Porter&rsquo;s analysis

3.6&nbsp;&nbsp;&nbsp; Competitive review, 2020

3.7&nbsp;&nbsp;&nbsp; PEST analysis

Chapter 4&nbsp;&nbsp;&nbsp;Europe Anti-viral Drugs Market, By Drug Class

4.1&nbsp;&nbsp;&nbsp; Market trends

4.2&nbsp;&nbsp;&nbsp; DNA Polymerase Inhibitors

4.2.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, by country, 2016 &ndash; 2027 (USD Million)

4.3&nbsp;&nbsp;&nbsp; Reverse Transcriptase Inhibitors

4.3.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, by country, 2016 &ndash; 2027 (USD Million)

4.4&nbsp;&nbsp;&nbsp; Protease Inhibitors

4.4.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, by country, 2016 &ndash; 2027 (USD Million)

4.5&nbsp;&nbsp;&nbsp; Neuraminidase Inhibitors

4.5.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, by country, 2016 &ndash; 2027 (USD Million)

4.6&nbsp;&nbsp;&nbsp; Others

4.6.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, by country, 2016 &ndash; 2027 (USD Million)

Chapter 5&nbsp;&nbsp;&nbsp;Europe Anti-viral Drugs Market, By Indication

5.1&nbsp;&nbsp;&nbsp; Market trends

5.2&nbsp;&nbsp;&nbsp; Influenza

5.2.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, by country, 2016 &ndash; 2027 (USD Million)

5.3&nbsp;&nbsp;&nbsp; HIV AIDS

5.3.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, by country, 2016 &ndash; 2027 (USD Million)

5.4&nbsp;&nbsp;&nbsp; Hepatitis

5.4.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, by country, 2016 &ndash; 2027 (USD Million)

5.5&nbsp;&nbsp;&nbsp; Herpes Simplex Virus (HSV)

5.5.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, by country, 2016 &ndash; 2027 (USD Million)

5.6&nbsp;&nbsp;&nbsp; Coronavirus infection

5.6.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, by country, 2016 &ndash; 2027 (USD Million)

5.7&nbsp;&nbsp;&nbsp; Others

5.7.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, by country, 2016 &ndash; 2027 (USD Million)

Chapter 6&nbsp;&nbsp;&nbsp;Europe Anti-viral Drug Market, By Type

6.1&nbsp;&nbsp;&nbsp; Market trends

6.2&nbsp;&nbsp;&nbsp; Branded

6.2.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, by country, 2016 &ndash; 2027 (USD Million)

6.3&nbsp;&nbsp;&nbsp; Generic

6.3.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, by country, 2016 &ndash; 2027 (USD Million)

Chapter 7&nbsp;&nbsp;&nbsp;Europe Anti-viral Drugs Market, By Age Group

7.1&nbsp;&nbsp;&nbsp; Market trends

7.2&nbsp;&nbsp;&nbsp; Adult

7.2.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, by country, 2016 &ndash; 2027 (USD Million)

7.3&nbsp;&nbsp;&nbsp; Pediatric

7.3.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, by country, 2016 &ndash; 2027 (USD Million)

7.4&nbsp;&nbsp;&nbsp; Geriatric

7.4.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, by country, 2016 &ndash; 2027 (USD Million)

Chapter 8&nbsp;&nbsp;&nbsp;Europe Anti-viral Drugs Market, By Country

8.1&nbsp;&nbsp;&nbsp; Market trends

8.2&nbsp;&nbsp;&nbsp; Germany

8.2.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, by drug class, 2016 &ndash; 2027 (USD Million)

8.2.2&nbsp;&nbsp;&nbsp; Market estimates and forecast, by indication, 2016 &ndash; 2027 (USD Million)

8.2.3&nbsp;&nbsp;&nbsp; Market estimates and forecast, by type, 2016 &ndash; 2027 (USD Million)

8.2.4&nbsp;&nbsp;&nbsp; Market estimates and forecast, by age group, 2016 &ndash; 2027 (USD Million)

8.3&nbsp;&nbsp;&nbsp; UK

8.3.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, by drug class, 2016 &ndash; 2027 (USD Million)

8.3.2&nbsp;&nbsp;&nbsp; Market estimates and forecast, by indication, 2016 &ndash; 2027 (USD Million)

8.3.3&nbsp;&nbsp;&nbsp; Market estimates and forecast, by type, 2016 &ndash; 2027 (USD Million)

8.3.4&nbsp;&nbsp;&nbsp; Market estimates and forecast, by age group, 2016 &ndash; 2027 (USD Million)

8.4&nbsp;&nbsp;&nbsp; France

8.4.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, by drug class, 2016 &ndash; 2027 (USD Million)

8.4.2&nbsp;&nbsp;&nbsp; Market estimates and forecast, by indication, 2016 &ndash; 2027 (USD Million)

8.4.3&nbsp;&nbsp;&nbsp; Market estimates and forecast, by type, 2016 &ndash; 2027 (USD Million)

8.4.4&nbsp;&nbsp;&nbsp; Market estimates and forecast, by age group, 2016 &ndash; 2027 (USD Million)

8.5&nbsp;&nbsp;&nbsp; Spain

8.5.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, by drug class, 2016 &ndash; 2027 (USD Million)

8.5.2&nbsp;&nbsp;&nbsp; Market estimates and forecast, by indication, 2016 &ndash; 2027 (USD Million)

8.5.3&nbsp;&nbsp;&nbsp; Market estimates and forecast, by type, 2016 &ndash; 2027 (USD Million)

8.5.4&nbsp;&nbsp;&nbsp; Market estimates and forecast, by age group, 2016 &ndash; 2027 (USD Million)

8.6&nbsp;&nbsp;&nbsp; Italy

8.6.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, by drug class, 2016 &ndash; 2027 (USD Million)

8.6.2&nbsp;&nbsp;&nbsp; Market estimates and forecast, by indication, 2016 &ndash; 2027 (USD Million)

8.6.3&nbsp;&nbsp;&nbsp; Market estimates and forecast, by type, 2016 &ndash; 2027 (USD Million)

8.6.4&nbsp;&nbsp;&nbsp; Market estimates and forecast, by age group, 2016 &ndash; 2027 (USD Million)

8.7&nbsp;&nbsp;&nbsp; Russia

8.7.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, by drug class, 2016 &ndash; 2027 (USD Million)

8.7.2&nbsp;&nbsp;&nbsp; Market estimates and forecast, by indication, 2016 &ndash; 2027 (USD Million)

8.7.3&nbsp;&nbsp;&nbsp; Market estimates and forecast, by type, 2016 &ndash; 2027 (USD Million)

8.7.4&nbsp;&nbsp;&nbsp; Market estimates and forecast, by age group, 2016 &ndash; 2027 (USD Million)

8.8&nbsp;&nbsp;&nbsp; Poland

8.8.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, by drug class, 2016 &ndash; 2027 (USD Million)

8.8.2&nbsp;&nbsp;&nbsp; Market estimates and forecast, by indication, 2016 &ndash; 2027 (USD Million)

8.8.3&nbsp;&nbsp;&nbsp; Market estimates and forecast, by type, 2016 &ndash; 2027 (USD Million)

8.8.4&nbsp;&nbsp;&nbsp; Market estimates and forecast, by age group, 2016 &ndash; 2027 (USD Million)

8.9&nbsp;&nbsp;&nbsp; Switzerland

8.9.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, by drug class, 2016 &ndash; 2027 (USD Million)

8.9.2&nbsp;&nbsp;&nbsp; Market estimates and forecast, by indication, 2016 &ndash; 2027 (USD Million)

8.9.3&nbsp;&nbsp;&nbsp; Market estimates and forecast, by type, 2016 &ndash; 2027 (USD Million)

8.9.4&nbsp;&nbsp;&nbsp; Market estimates and forecast, by age group, 2016 &ndash; 2027 (USD Million)

8.10&nbsp;&nbsp;&nbsp; The Netherlands

8.10.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, by drug class, 2016 &ndash; 2027 (USD Million)

8.10.2&nbsp;&nbsp;&nbsp; Market estimates and forecast, by indication, 2016 &ndash; 2027 (USD Million)

8.10.3&nbsp;&nbsp;&nbsp; Market estimates and forecast, by type, 2016 &ndash; 2027 (USD Million)

8.10.4&nbsp;&nbsp;&nbsp; Market estimates and forecast, by age group, 2016 &ndash; 2027 (USD Million)

8.11&nbsp;&nbsp;&nbsp; Sweden

8.11.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, by drug class, 2016 &ndash; 2027 (USD Million)

8.11.2&nbsp;&nbsp;&nbsp; Market estimates and forecast, by indication, 2016 &ndash; 2027 (USD Million)

8.11.3&nbsp;&nbsp;&nbsp; Market estimates and forecast, by type, 2016 &ndash; 2027 (USD Million)

8.11.4&nbsp;&nbsp;&nbsp; Market estimates and forecast, by age group, 2016 &ndash; 2027 (USD Million)

Chapter 9&nbsp;&nbsp;&nbsp;Company Profiles

9.1&nbsp;&nbsp;&nbsp; Gilead Science, Inc

9.1.1&nbsp;&nbsp;&nbsp; Business overview

9.1.2&nbsp;&nbsp;&nbsp; Financial data

9.1.3&nbsp;&nbsp;&nbsp; Drug class landscape

9.1.4&nbsp;&nbsp;&nbsp; Strategic outlook

9.2&nbsp;&nbsp;&nbsp; Johnson &amp; Johnson

9.2.1&nbsp;&nbsp;&nbsp; Business overview

9.2.2&nbsp;&nbsp;&nbsp; Financial data

9.2.3&nbsp;&nbsp;&nbsp; Drug class landscape

9.2.4&nbsp;&nbsp;&nbsp; Strategic outlook

9.3&nbsp;&nbsp;&nbsp; AstraZeneca

9.3.1&nbsp;&nbsp;&nbsp; Business overview

9.3.2&nbsp;&nbsp;&nbsp; Financial data

9.3.3&nbsp;&nbsp;&nbsp; Drug class landscape

9.3.4&nbsp;&nbsp;&nbsp; Strategic outlook

9.4&nbsp;&nbsp;&nbsp; GlaxoSmithKline

9.4.1&nbsp;&nbsp;&nbsp; Business overview

9.4.2&nbsp;&nbsp;&nbsp; Financial data

9.4.3&nbsp;&nbsp;&nbsp; Drug class landscape

9.4.4&nbsp;&nbsp;&nbsp; Strategic outlook

9.5&nbsp;&nbsp;&nbsp; Abbvie, Inc

9.5.1&nbsp;&nbsp;&nbsp; Business overview

9.5.2&nbsp;&nbsp;&nbsp; Financial data

9.5.3&nbsp;&nbsp;&nbsp; Drug class landscape

9.5.4&nbsp;&nbsp;&nbsp; Strategic outlook

9.6&nbsp;&nbsp;&nbsp; Merck &amp; Co.,

9.6.1&nbsp;&nbsp;&nbsp; Business overview

9.6.2&nbsp;&nbsp;&nbsp; Financial data

9.6.3&nbsp;&nbsp;&nbsp; Drug class landscape

9.6.4&nbsp;&nbsp;&nbsp; Strategic outlook

9.7&nbsp;&nbsp;&nbsp; Bristol Myers Squib

9.7.1&nbsp;&nbsp;&nbsp; Business overview

9.7.2&nbsp;&nbsp;&nbsp; Financial data

9.7.3&nbsp;&nbsp;&nbsp; Drug class landscape

9.7.4&nbsp;&nbsp;&nbsp; Strategic outlook

9.8&nbsp;&nbsp;&nbsp; Mylan N.V.

9.8.1&nbsp;&nbsp;&nbsp; Business overview

9.8.2&nbsp;&nbsp;&nbsp; Financial data

9.8.3&nbsp;&nbsp;&nbsp; Drug class landscape

9.8.4&nbsp;&nbsp;&nbsp; Strategic outlook 
&nbsp;

Request sample

Need Help?

Contact us

Get In Touch

Address

Contact

Phone :

Email:

Company

Information

Links